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INTRODUCTION: Obesity increases triglyceride levels and decreases high-density lipoprotein concentrations in plasma. Artificial 
emulsions resembling lipidic plasma lipoprotein structures have been used to evaluate low-density lipoprotein metabolism. In grade 
III obesity, low density lipoprotein metabolism is poorly understood. 
OBJECTIVE: To evaluate the kinetics with which a cholesterol-rich emulsion (called a low-density emulsion) binds to low-density 
lipoprotein receptors in a group of patients with grade III obesity by the fractional clearance rate. 
METHODS: A low-density emulsion was labeled with [14C]-cholesterol ester and [3H]-triglycerides and injected intravenously into 
ten normolipidemic non-diabetic patients with grade III obesity [body mass index higher than 40 kg/m2] and into ten non-obese 
healthy controls. Blood samples were collected over 24 hours to determine the plasma decay curve and to calculate the fractional 
clearance rate. 
RESULTS: There was no difference regarding plasma levels of total cholesterol or low-density lipoprotein cholesterol between the 
two groups. The fractional clearance rate of triglycerides was 0.086 ± 0.044 in the obese group and 0.122 ± 0.026 in the controls 
(p = 0.040), and the fractional clearance rate of cholesterol ester (h-1) was 0.052 ± 0.021 in the obese subjects and 0.058 ± 0.015 
(p = 0.971) in the controls. 
CONCLUSION: Grade III obese subjects exhibited normal low-density lipoprotein removal from plasma as tested by the nano-
emulsion method, but triglyceride removal was slower. 
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INTRODUCTION
The alterations in plasma lipids related to obesity that 
contribute to the higher incidence of cardiovascular disease 
in obese subjects mainly involve hypertriglyceridemia1,2 
and low serum high-density lipoprotein (HDL) cholesterol. 
Increases in low-density lipoprotein (LDL) cholesterol levels 
are less frequent3,4 and have been less well investigated. 
Lipidic emulsions of defined composition that are 
made without protein can mimic the intravascular behavior 
of plasma lipoproteins. Injected into the bloodstream, 
chylomicron-like or LDL-like emulsions acquire circulating 
apolipoproteins that modulate the emulsion’s metabolism 
and thus serve as a probe of the metabolic status of 
lipoproteins. 
Accumulation of LDL in the plasma leading to 
hypercholesterolemia is mostly due to reduced LDL plasma 
clearance by the LDL receptors rather than increased 
lipoprotein production. In a recent study that used LDL-like 
nanoemulsions to probe LDL metabolism, we observed 
that, in sedentary subjects, LDL removal from the plasma 
compartment was slower than in athletes, although there was 
no difference in LDL cholesterol between sedentary subjects 
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and athletes.5 This suggests that the increased removal of 
LDL in athletes is compensated for by an increased input 
of lipoprotein into plasma, either by increased conversion 
of LDL from VLDL or by increased direct LDL synthesis 
by the liver. To verify whether there are defects in LDL 
intravascular catabolism in obese subjects, we tested the 
plasma clearance of an LDL-like nanoemulsion in subjects 
with morbid grade III obesity (body mass index (BMI) >40 
kg/m2) in comparison with control subjects (25 kg/m2) of 
normal weight.
METHODS
Ten obese (three male and seven female) and ten non-
obese (four male and six female) subjects participated in 
the study. All participants were volunteers selected from 
the outpatient clinics of the institution. None of them were 
addicted to alcohol or had diabetes mellitus, liver, renal, 
thyroid, inflammatory, or neoplastic disease, and none were 
pregnant.
The design and objectives of the study were explained 
to the participants, and written informed consent was 
obtained. The study was approved by the Scientific and 
Ethics Committee. 
Blood samples for the determination of plasma 
lipids and apolipoproteins were collected after a 12-h 
fast. Commercial enzymatic methods were used for the 
determination of total cholesterol (Boehinger-Mannheim, 
Penzberg, Germany), triglycerides (Abbott Laboratories) 
and HDL cholesterol after chemical precipitation 
of apo-B-containing lipoproteins with magnesium 
phosphotungstate. LDL cholesterol was calculated by 
the formula of Friedewald.6 Plasma apo AI and apo B 
were assayed by radial immunodiffusion (Lipo-Partigen 
R-ApoA-I and Nor-Partigen R-ApoB plates, Behing, 
Marburg, Germany). The LDL-like nanoemulsion was 
prepared from a lipid mixture composed of 40 mg /
mmol egg phosphatidylcholine, 20 mg /mmol cholesteryl 
oleate,  1 mg /mmol triolein, and 0.5 mg /mmol 
cholesterol purchased from Sigma Chemical Co. (St 
Louis, MO), in addition to a mixture of [14C]cholesteryl 
oleate and [3H]-triglycerides purchased from Amersham 
International (Amersham, UK). Emulsification of the 
lipids by prolonged ultrasonic irradiation in aqueous 
media and two-step ultracentrifugation of the crude 
emulsion with density adjustment by the addition of KBr 
in order to obtain the LDE microemulsion was carried 
out by the method of Ginsburg et al.7 as modified by 
Maranhão et al.8 
The participants fasted for 12 h prior to the test at 9 
AM, but they were allowed two standard meals during the 
study at 12:30 PM and 6 PM. The LDL-like nanoemulsion 
containing 70 kBq of [14C] cholesteryl oleate and 121 kBq 
of [3H] triacylglycerol at a total of 5–6 mg /mmol in a 100-
µl volume was intravenously injected in a bolus. Plasma 
samples were collected over 24 h; the first sample was 
collected 5 minutes after the injection of the nanoemulsion, 
and, after that, at 1, 2, 4, 6, 8, 12, and 24 h after the injection. 
The safety of the radioactive dose injected into 
the subjects was assured according to radioprotection 
regulations9 described elsewhere.10 The procedures for lipid 
extraction and the addition of scintillation solution to each 
blood sample for radioactive counting and determination of 
the plasma decay curves of the radiosotopic labels of the 
nanoemulsion were performed as described previously using 
the ANACOMP software.11 
All recorded variables were tabulated as means ±SD 
or SEM. The normality of the data was tested by the 
Kolmogorov Smirnov test. Differences in the plasma lipids 
were evaluated using the Mann Whitney test, and differences 
with p <0.05 were considered statistically significant for all 
comparisons. All statistical calculations were performed with 
the software SPSS® for Windows, version 10.0.
The safety of the radioactive dose intravenously injected 
into the patients was assured according to the regulations of 
the International Commission on Radiological Protection.9 
The equivalent dose derived from the injected dose for each 
experiment was 0.1233 mSv, well below the 20-mSV annual 
limit for the intake of radionuclides.
RESULTS 
Table 1 shows the individual physical characteristics 
and the plasma lipid and apolipoprotein profiles of the 
obese subjects and the controls. Obese subjects had LDL 
cholesterol levels similar to those of the controls, but the 
HDL cholesterol values were lower. On the other hand, 
fasting triglyceride levels were greater in the obese subjects 
(p= 0.019) than in the controls. The apo B and apo A1 values 
were equal.
Figure 1 shows the decay curves of the cholesteryl ester 
label of the nanoemulsion. It is apparent that the curves 
obtained from the obese subjects did not differ from those 
of the non-obese controls. In fact, the calculated cholesteryl 
ester FCR of the morbid obese subjects was equal to that 
of the controls. The triglyceride FCR was lower in the 
morbid obese subjects than in the non-obese controls. In 
the non-obese controls, the triglyceride FCR was greater 
than that of the cholesteryl esters. In the obese, there was 
a trend (although not statistically significant) of a greater 
triglyceride FCR in comparison to the cholesteryl ester FCR. 
(Table 2) 
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DISCUSSION
In this study, in a group of morbid obese subjects, the 
removal of cholesteryl esters of an LDL-like nanoemulsion 
from plasma was similar to that observed in control subjects, 
but triglyceride removal was slower.
Injected into the blood stream, the LDL-like 
nanoemulsion acquires several circulating apolipoproteins 
such as apo CII and apo E. Apo CII is the co-factor for 
lipoprotein lipase and can eventually stimulate the enzyme 
to break down the residual triglycerides present in this 
nanoemulsion. On the other hand, apo E is recognized by the 
receptors that remove LDL from circulation.12
In several studies from our group, a triglyceride-
rich emulsion labeled with radioactive triglycerides and 
cholesteryl esters has been used to test the chylomicron 
metabolic pathway in several disorders that affect plasma 
lipid metabolism.13-19 This pathway is also common to 
very-low-density lipoproteins (VLDL) that (similarly to 
chylomicrons) undergo degradation of their triglyceride 
content by lipoprotein lipase using apo CII as a co-factor.
In obese subjects, the removal of the triglycerides of 
the chylomicron-like emulsion from plasma was similar 
to that in the non-obese controls, but the cholesteryl ester 
removal was slower.20 This finding suggests that, although 
the lipolysis process occurs normally in the obese, there 
is difficulty in removing the remnants from circulation, a 
defect that is associated with atherosclerosis development. 
In the correlation study on obese subjects that was 
subsequently performed, a negative correlation between 
cholesteryl ester removal (i.e., remnant removal) and BMI 
was found; in contrast, lipolysis correlated positively with 
BMI.21 One can hypothesize that the excess insulin in the 
plasma of obese subjects stimulates lipolysis, whereas their 
obesity inhibits the mechanisms of remnant removal, in 
which LDL receptors are also involved. However, when 
the morbidly obese were compared with obese subjects, 
the former showed diminished lipolysis, indicating that 
additional defects appear in individuals with extremely 
high BMIs. Another aspect is alterations in glucagon-
like peptide 1, which modifies the postprandial rise in 
triglyceride concentration, whose effects are not completely 
understood in morbid obesity, despite the functions already 
described.22,23 Yet another aspect which may be mentioned is 
Table 1 - Individual physical characteristics and plasma 
lipid and apolipoprotein profiles (means ± SD) for obese 
and control subjects
Study group p
Grade III obese subjects
(mean ± SD)
Controls
(mean ± SD)
Age (years) 44 ± 10 46 ± 12 0.684
BMI (kg/m2) 48 ± 5 22 ± 3 <0.001
Cholesterol 
(mg /dL)
199 ± 32 186 ± 23 0.481
LDL-C 45 ± 10 58 ± 17 0.043
HDL-C 21 ± 10 29 ± 7 0.043
Triglycerides 
(mg /dL)
144 ± 32 101 ± 45 0.019
Apo A-I (g/L) 1.34 ± 0.20 1.39 ± 0,27 0.898
Apo B (g/L) 0.80 ± 0.22 0.90 ± 0.21 0.606
BMI = body mass index; HDL-C = high-density lipoprotein cholesterol; 
LDL-C = low-density lipoprotein cholesterol; Apo = apolipoprotein 
Table 2 - Fractional clearance rate of the emulsion in obese 
and control subjects
Group (n) p
Grade III obese subjects
(mean ± SD)
Controls
(mean ± SD)
FCR-TG (h-1) 0.086 ± 0.044 0.122 ± 0.026 0.040
FCR-CE (h-1) 0.052 ± 0.021 0.058 ± 0.015 0.971
FCR -TG (h-1): fractional clearance rate of triglycerides
FCR -CE (h-1): fractional clearance rate of cholesterol esters
Figure 1 - Decay curves of the [3H]-triglyceride emulsion obtained from 
obese and control subjects. The labeled emulsion was intravenously injected 
in a bolus, and blood samples were drawn at pre-established intervals over 
24 h for measurement of radioactivity in a scintillation solution.
Figure 2 - Decay curves of the [14C]-cholesteryl oleate emulsion obtained 
from obese and control subjects. The labeled emulsion was intravenously 
injected in a bolus, and blood samples were drawn at pre-established inter-
vals over 24 h for measurement of radioactivity in a scintillation solution. 
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the fact that treatment of obese patients with the cholesterol 
removing agent sibutramine does not appear to correct the 
hypertension normally associated to obesity.24 
Whereas the chylomicron-like emulsion probes 
the lipolysis and remnant removal of triglyceride-rich 
lipoproteins, the LDL-like nanoemulsion probes the 
function of the mechanisms that remove LDL from 
circulation. The fact that the removal of the LDL-like 
nanoemulsion was normal in the morbidly obese indicates 
that those mechanisms are not altered in these subjects. 
This was confirmed by the fact that LDL cholesterol and 
apolipoprotein B concentrations were both normal, although 
different removal rates associated with different synthesis 
rates might have resulted in equal LDL concentrations, 
a possibility that we explored in this study regarding the 
removal rates. 
The fact that, in both control and obese subjects, the 
triglycerides of the LDL-like emulsion were removed 
faster than the cholesteryl ester indicates that lipolysis 
also occurs in those particles as it does in chylomicron-
like emulsions. The finding that the triglycerides of the 
LDL-like nanoemulsion were removed more slowly in the 
morbidly obese than in the controls is noteworthy. There 
are significant structural differences between LDL-like 
particles and chylomicron-like emulsion particles. While in 
the chylomicron-like emulsion, the triglyceride component is 
prevalent, constituting up to 70% of the particle composition, 
in LDL-like particles, the triglyceride content is rather 
residual. On the other hand, the particle diameter of the 
chylomicron-like emulsion is two to four times greater 
than that of the LDL-like preparation. Nonetheless, both 
preparations showed slower triglyceride removal in the 
morbidly obese subjects (but not in the obese subjects), as 
compared with the controls. 
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